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Immunogenic antigens for vaccination are often created
through the production of recombinant proteins using Escher-
ichia coli.1 As a side product, aggregates called inclusion bodies
(IBs) are formed, containing largely misfolded forms of the
overexpressed recombinant protein.2 The effect of IBs on the
immune system and whether they can be used as effective
vaccine products remain unknown. The non-native conforma-
tion of proteins upon accumulation in IBs abrogates their use as
vaccines aimed at generating high-afﬁnity antibodies.3 However,
IBs exhibit unique properties, including mechanical and thermal
stability due to their intrinsic particulate nature, biocompat-
ibility, high antigenic content, low toxicity and relative
resistance to proteases. These characteristics make IBs attractive
as an antigenic vaccine formulation for T cell responses to linear
epitopes. Whether IBs can trigger adaptive cellular responses
initiated via uptake by dendritic cells for presentation to T cells
is unknown.
We generated IBs containing the ovalbumin (OVA)-derived
OT-I and OT-II epitopes using the TorA signal sequence in E. coli
(Fig. 1a), as previously described.4 Since dendritic cells (DCs) are
the primary cell type responsible for the activation of T cells, we
ﬁrst analyzed the inherent immunogenic capacity of IBs directly
on these cells. IBs were derived from E. coli by cell disruption
and centrifugation (Crude), as well as additional processing by
sequential washing (Processed; Fig. 1b). Bone marrow-derived
dendritic cells (BMDCs) were cultured from the bone marrow of
C57Bl/6 wild-type mice, as previously described.5 Immunogenic
maturation of BMDCs was measured by the expression of the
costimulatory markers CD70, CD80, and CD86, and the MHC
Class I and II complexes using ﬂow cytometry. Both unprocessed
(Crude) and processed IBs induced the expression of CD70,
CD80, CD86, and MHC class I in a concentration-dependent
manner, whereas MHC class II was downregulated by IBs at
higher (100 nM) concentrations, as was observed with LPS
(Fig. 1c). Additionally, splenic CD11c+ DCs showed similar
concentration-dependent maturation by IBs as BMDCs.
Although IBs are particulate aggregates that are structurally
resistant to detoxiﬁcation methods, such as Triton-mediated
phase separation (removing free LPS), IBs are rarely endotoxin
free.6 Since endotoxins such as LPS are sensed by TLR4 on
innate immune cells, resulting in MyD88-mediated NFκB
activation,7 we tested the effect of IB-induced maturation on
MyD88-deﬁcient BMDCs. Interestingly, loss of MyD88 in BMDCs
completely abrogated IB-induced maturation (Fig. 1d), suggest-
ing that intact TLR signaling is required for IBs to induce
maturation in DCs. Although free LPS is effectively absent in
processed IBs, the maturation of BMDCs by processed IBs
remained MyD88-dependent and was independent of antigen
content since both OVA-containing (Fig. 1d; green and red) and
GFP-containing IBs (Blue; Fig. 1d) induced MyD88-dependent DC
maturation. In summary, IBs show an inherent capacity to induce
DC maturation that is dependent on the presence of MyD88,
downstream of TLR signaling.
IBs have strong DC maturation capability, indicating their
potential as vaccine candidates, since DC maturation is required
for the effective priming of naïve CD8+ and CD4+ T cells.
However, it is unknown whether DCs can internalize and process
IB-included antigens for antigen presentation. Therefore, we
tested the capacity of processed IBs to induce antigen
presentation by DCs to CD8+ and CD4+ T cells. BMDCs were
cultured in the presence of OVA-IBs, engineered to include OVA-
derived OT-I and OT-II epitopes, or ovalbumin protein for 3 h,
extensively washed and cocultured with antigen-speciﬁc CFSE-
labeled OT-I CD8+ or CD4+ O-TII transgenic T cells for 3 days
(Fig. 1e). We observed concentration-dependent proliferation
and production of IFNγ by both antigen-speciﬁc OT-I CD8+ T cells
and OT-II CD4+ T cells after coculture with IB-pulsed BMDCs
(Fig. 1e). Puriﬁed splenic CD11c+ DCs loaded with OVA-IBs were
also capable of inducing antigen-speciﬁc proliferation and IFNγ
production in both CD8+ and CD4+ T cells (Fig. 1f). Proliferation
and IFNγ production induced by IBs were signiﬁcantly higher
than those induced by equal amounts of synthetic long peptide
containing OT-I and OT-II sequences. Hence, both cultured
BMDCs and isolated CD11c+ splenic DCs take up, process and
present IB-derived antigens to CD8+ and CD4+ T cells.
The uptake, processing and presentation of exogenous antigen
on MHC class I to CD8+ T cells is a process called cross-
presentation.8 TLR4 engagement, MyD88 signaling and DC
maturation by LPS have previously been shown to enhance
cross-presentation.9 Therefore, we tested the capacity of BMDCs
from MyD88-deﬁcient mice to cross-present IB-derived antigen
to CD8+ T cells. MyD88-deﬁcient BMDCs showed a reduction in
CD8+ T cell activation, while CD4+ T cell activation was
unaffected (Fig. 1g). Quantiﬁcation of the preference for
cross-presentation (calculated percentage of initially responded
CD8+ T cells divided by CD4+ T cells) showed a signiﬁcant
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Fig. 1 a Ova A polypeptide containing the indicated OT-I and OT-II epitopes and GFP were produced in inclusion bodies (IBs) upon N-terminal
fusion to IB tag ssTorA(3×).4 Ova B polypeptide was produced in IBs upon fusion of a truncated ssTorA(3×) derivative (Jong, Luirink, manuscript
in preparation) at both termini. b IB production and processing was performed as described4 and include sequential washing with Triton
X-100 to remove excess membrane material, including LPS, urea to break low-afﬁnity protein interactions and NaCl and high salt to break
potential electrostatic protein interactions (processed). c Bone marrow-derived dendritic cells (BMDCs, from C57BL/6 WT mice, 7 days GM-CSF
cultured5) and splenic CD11c+ dendritic cells, which were isolated by magnetic beads (MagniSort™/Thermo Fisher; 8802-6861-74) and pulsed
with IBs (both crude and processed), show concentration-dependent maturation as measured by FACS. d DC maturation induced by IBs in
BMDCs from WT or MyD88-deﬁcient mice. e DC-mediated antigen presentation was measured as proliferation (CFSE dilution as described
previously10) and IFNγ production (intracellular staining FACS) by antigen-speciﬁc CD8+ OT-I and CD4+ OT-II transgenic T cells after 3 days of
coculture with product-pulsed BMDCs. f CD11c+ splenic dendritic cells puriﬁed by magnetic CD11c-bead isolation were tested for antigen
presentation to CD8+ and CD4+ T cells. g OVA-IB-pulsed MyD88−/− BMDCs show signiﬁcantly decreased levels of CD8+ T cell activation, but
not CD4+ T cells, compared to WT BMDCs. h BMDCs were cultured with product either 24 or 0 h before coculture with CD8+ OT-I and CD4+
OT-II transgenic T cells to test the long-term antigen presentation capacity of IB-pulsed BMDCs. The effect of 24 h of processing had
little effect on the cross-presentation of IB-pulsed BMDCs to CD8+ T cells but highly reduced CD4+ T cell activation. i C57BL/6 WT mice were
subcutaneously immunized with 5 nmol OVA-IB with 25 µg agonistic CD40 antibody. After 7 days, the mice were sacriﬁced, and
the splenocytes were analyzed by ﬂow cytometry to detect OVA antigen-speciﬁc CD8+ T cells by H2-Kb OVA-tetramer staining. Representative
experiments with both OVA-A and OVA-B IBs. j OVA-IBs induced de novo antigen-speciﬁc CD8+ T cell responses in vivo. k Mice (N= 9 per
group) were immunized with 5 nmol OVA-B IBs in combination with a variety of adjuvants, and antigen-speciﬁc CD8+ T cells in the
splenocytes were measured by FACS using H2-Kb OVA-tetramer staining. l. The splenocytes from immunized mice were restimulated for 6 h
with 10 µg/ml OVA-derived SIINFEKL short peptide in the presence of brefeldin A, and IFNγ/TNFα production by CD8+ T cells was measured by
intracellular FACS staining.m Similarly, CD4+ T cells were restimulated with the OVA-derived ISQAVHAAHAEINEAGR short peptide for 48 h, and
IFNγ was measured by intracellular FACS staining. All data are representative of at least two individual experiments. In vitro experiments were
performed as biological triplicates, and OVA-A IBs were used. In vivo experiments were performed using both OVA-A and OVA-B IBs, yielding
comparable results. Graphs show the mean ± SEM. Statistics applied by GraphPad PRISM 7.0; D/H/J unpaired Fisher’s t-test, F/G/K/L/M one-way
ANOVA with Tukey’s post hoc comparison; *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001
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decrease in cross-presentation when MyD88 signaling was lost.
Hence, intact TLR-MyD88 signaling is required for optimal cross-
presentation of IB-derived antigens. Lastly, we hypothesized that
the increase in antigen presentation of IB-derived antigens was
due to intracellular depot-formation and slow release of antigen
from internalized IBs. To test this, we incubated BMDCs with IBs
(for 3 h and with extensive post-incubation washing) 24 h before
T cell coculture or without the 24-h preincubation (Fig. 1h).
Interestingly, no reduction of CD8+ T cell activation induced by
IBs was observed when DCs were preincubated with IBs,
suggesting intact and continued cross-presentation (Fig. 1h). In
contrast, CD4+ T cell activation was signiﬁcantly decreased with
preincubation for 24 h, suggesting that MHC class II-mediated
antigen presentation to CD4+ T cells occurs mostly within the
ﬁrst 24 h after IB incubation.
Having veriﬁed the capacity of IBs to induce DC-mediated
antigen presentation to T cells, we next investigated the capacity
of IBs to generate de novo cellular responses in vivo. First, we
subcutaneously injected OVA-IBs with agonistic CD40 antibody
in mice, and after 7 days, measured the percentage of
ovalbumin-speciﬁc CD8+ T cells in splenocytes by ﬂow cytometry
using an H2-Kb OVA-tetramer (Fig. 1i). A signiﬁcant induction in
antigen-speciﬁc CD8+ T cells was observed in the splenocytes of
immunized mice after 7 days (Fig. 1j). IBs without any additional
adjuvants did not induce detectable antigen-speciﬁc CD8+
T cells (data not shown). To test whether the induction of
cellular responses could be further optimized, we vaccinated
mice with IBs combined with a selection of adjuvants known to
boost CD8+ T cell responses, including agonistic CD40, Poly I:C,
AddaVax (MF59) and STING ligand (DMXAA). AddaVax and
agonistic CD40 induced the highest frequency of CD8+ T cells
as measured by tetramer staining (Fig. 1k). When IBs were
combined with agonistic CD40 or AddaVax, the highest
frequency of CD8+ T cells producing the effector cytokines IFNγ
and TNFα after peptide restimulation was found (Fig. 1l).
Surprisingly, the frequency of CD4+ T cells producing IFNγ upon
peptide restimulation showed an inverse correlation to the CD8+
T cell responses (Fig. 1m). Hence, the adjuvants may determine
the magnitude of the CD8+ or CD4+ T cell response to IBs. In
summary, we experimentally showed the potency of IBs to be
used as a vaccine to induce both strong antigen-speciﬁc CD8+
and CD4+ T cell responses.
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